Evaxion is launching a significant improvement of its already leading AI-platform, AI-Immunology, with a new automated vaccine design module. “We are very excited to launch this latest improvement of AI-Immunology, achieving yet another of our milestones for 2025. The new modules significantly enhance our value proposition towards potential partners and increase our in-house capabilities. The continued development, expansion and refinement of the platform remains a cornerstone of our strategy as a leader in AI-based vaccine discovery and design,” says Birgitte Rono, CSO and interim CEO of Evaxion.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion to Present New Data on AI-Designed Cancer Vaccine at SITC 2025
- Merck’s In-Licensing of Evaxion’s Vaccine Candidate Boosts Buy Rating and Price Target
- Evaxion Biotech price target raised to $16 from $14 at H.C. Wainwright
- Evaxion Out-Licenses Vaccine Candidate EVX-B3 to MSD
- Evaxion Biotech out-licensed vaccine candidate EVX-B3 to MSDMerck